ArticleEndocrine oncology (Bristol, England)2025
Macrophage abundance in oncocytic thyroid cancer is associated with PD-L1 expression.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026Review
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Oncocytic thyroid cancer (OTC) accounts for 3-5% of thyroid cancers. Previously classified as a subtype of follicular thyroid cancer (FTC), OTC has been redefined by the World Health Organization due to its distinct histopathological and molecular features. OTC demonstrates a more aggressive clinical course than other differentiated thyroid cancers, with higher rates of distant metastases and is often refractory to radioactive iodine therapy (RAI). This study investigates the transcriptional profiles and immune populations of OTC and FTC to identify key differences in gene signatures and immune cell populations. Methods: We conducted a comparative analysis of the transcriptional profiles of OTC ( Results: Functional enrichment analysis of differentially expressed genes between OTC and non-neoplastic thyroids revealed upregulation of metabolic pathway genes and downregulation of genes from the cytokine-cytokine receptor pathway. Compared to FTC, OTC cases have decreased expression of thyroid differentiation genes. Conclusions: The heightened metabolic activity and reduced differentiation of OTC revealed by our transcriptional studies correlate with clinical features such as FDG-PET avidity and diminished RAI response. Marked PD-L1 upregulation in widely invasive OTC suggests immune checkpoint inhibition as a potential therapeutic strategy. Larger, independent studies will be critical to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.